G
Gilles Thibault
Researcher at François Rabelais University
Publications - 75
Citations - 2800
Gilles Thibault is an academic researcher from François Rabelais University. The author has contributed to research in topics: Antibody & CD8. The author has an hindex of 26, co-authored 73 publications receiving 2517 citations. Previous affiliations of Gilles Thibault include Centre national de la recherche scientifique & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Emilie Mamessier,Aude Sylvain,Marie-Laure Thibult,Gilles Houvenaeghel,Jocelyne Jacquemier,Rémy Castellano,Anthony Gonçalves,Pascale Andre,François Romagné,Gilles Thibault,Patrice Viens,Daniel Birnbaum,François Bertucci,Alessandro Moretta,Daniel Olive +14 more
TL;DR: The data show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity, highlighting the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitUMor immunity.
Journal ArticleDOI
Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship
Sebastien Dall'ozzo,Sophie Tartas,Gilles Paintaud,Guillaume Cartron,Philippe Colombat,Pierre Bardos,Hervé Watier,Gilles Thibault +7 more
TL;DR: This study supports the conclusion that FCGR3A genotype is associated with response to rituximab because it affects the relationship between ritUXimab concentration and NK cell-mediated lysis of CD20+ cells.
Journal ArticleDOI
Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.
TL;DR: Rituximab induces substantial T cell depletion, mainly of CD4+ cells, which is associated with the clinical response in RA, and this mechanism of action may depend at least in part on T cells.
Journal ArticleDOI
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
Bruno Coudert,Jean-Yves Pierga,Marie-Ange Mouret-Reynier,Kaldoun Kerrou,Jean-Marc Ferrero,Thierry Petit,Pierre Kerbrat,Pierre-Francois Dupre,Thomas Bachelot,Philippe Gabelle,Sylvia Giard,David Coeffic,Philippe Bougnoux,Jean-Briac Prevost,Gilles Paintaud,Gilles Thibault,Juana Hernandez,Mathieu Coudert,Laurent Arnould,Alina Berriolo-Riedinger +19 more
TL;DR: The AVATAXHER trial aimed to predict pathological complete response early with the use of PET and to investigate whether the addition of bevacizumab could improve the proportion of patients achieving a pathologicalcomplete response in patients unlikely to respond to treatment.
Journal Article
Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism.
Tony Avril,A C Jarousseau,Hervé Watier,Boucraut J,Le Bouteiller P,Pierre Bardos,Gilles Thibault +6 more
TL;DR: The results demonstrate that the resistance of CC to NK lysis mainly involves an HLA class I-independent mechanism(s), and show that the expression of a classical class I target molecule (HLA-B7) on JAR cells is insufficient to induce lysis by allospecific polyclonal CTL.